Stroke
RSSArticles
-
FDA actions
-
Aliskiren and ACEIs/ARBs don't mix
-
Benefits of treating systolic hypertension
-
Bleeding concerns with dabigatran
-
Short course treatment for latent TB
-
All antidepressants are created equal
-
Adverse drug events in the elderly
-
Warfarin testing every 12 weeks?
-
Rivaroxaban for atrial fibrillation patients
Rivaroxaban (Xarelto), Janssen Pharmaceutical's once-a-day oral Xa inhibitor, has been approved for reducing the risk of stroke in patients with atrial fibrillation. -
FDA actions